- Home
- Publications
- Publication Search
- Publication Details
Title
Promising New Agents for Colorectal Cancer
Authors
Keywords
Metastatic colorectal cancer, Therapeutics, Microsatellite instability, RAS, BRAF, HER2
Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 19, Issue 6, Pages -
Publisher
Springer Nature
Online
2018-05-11
DOI
10.1007/s11864-018-0543-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic Potential of Targeting Wnt/β-Catenin Pathway in Treatment of Colorectal Cancer: Rational and Progress
- (2017) Afsane Bahrami et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC).
- (2017) Howard S. Hochster et al. JOURNAL OF CLINICAL ONCOLOGY
- BBI608-224: A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) administered with panitumumab in KRAS wild-type patients with metastatic colorectal cancer.
- (2017) Tim Larson et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer
- (2017) Efrat Dotan et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Glutaminase sustains cell survival via the regulation of glycolysis and glutaminolysis in colorectal cancer
- (2017) Zhou Song et al. Oncology Letters
- Targeting BRAF -Mutant Colorectal Cancer: Progress in Combination Strategies
- (2017) Raghav Sundar et al. Cancer Discovery
- Use of selective inhibition of nuclear export (SINE) using a CRM1/XPO1 antagonist to overcome resistance to CPT-11 in colon cancer in preclinical models.
- (2017) Hye Won Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and antitumor activity of selinexor (KPT-330), a first-in-class, oral XPO1 selective inhibitor of nuclear export: A phase I study expanded with colon cancer cohort.
- (2017) Morten Mau-Soerensen et al. JOURNAL OF CLINICAL ONCOLOGY
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- (2016) Andrea Sartore-Bianchi et al. LANCET ONCOLOGY
- CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors
- (2016) Marina Bacac et al. OncoImmunology
- Targeting Wnt signaling in colorectal cancer. A Review in the Theme: Cell Signaling: Proteins, Pathways and Mechanisms
- (2015) Laura Novellasdemunt et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Phase II pharmacodynamic trial of palbociclib in patients with KRAS mutant colorectal cancer.
- (2015) Mark H. O'Hara et al. JOURNAL OF CLINICAL ONCOLOGY
- IMMU-130, a unique antibody-drug conjugate (ADC) of SN-38 targeting CEACAM5 antigen: Preclinical basis for clinical activity in metastatic colorectal cancer (mCRC).
- (2015) Serengulam V. Govindan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
- (2015) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- (2015) Robert J. Mayer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
- (2012) Ryan B. Corcoran et al. CANCER CELL
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas
- (2012) Claire Palles et al. NATURE GENETICS
- Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy
- (2009) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started